Business Wire
14 Nov 2025, 11:45 UTC · 44w ago
Verdict
Headline takes no side. We score CDTX +1.00 across two claims — strongly bullish.
+1.00strongly bullish
More positive than 98% of ticker scores this week
What the story claims
2 claims · scored −1 bearish … +1 bullish
Merck has entered into a definitive agreement to acquire Cidara Therapeutics for $221.50 per share in cash.
So whatA definitive acquisition agreement at a specific cash price provides immediate, high-certainty valuation for the target company (CDTX).
More positive than 98% of claims this week
The total transaction value for the acquisition of Cidara is approximately $9.2 billion.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 76% of claims this week
Which stocks this story touches
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Reuters
21h ago
+108.9%
Price agrees with the score
$221.38 vs $105.99 close before publication (Nov 13) · not market-adjusted
CDTX chart →
